Pilot study to evaLuate the role of high-dose rAnibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with perSistent/recurrenT macular fluid <30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study)

Eye (Basingstoke)

Volumn 26, Issue 9, 2012, Pages 1181-1187

  Fung, A T ^a   Kumar, N ^a   Vance, S K ^a   Slakter, J S ^a   Klancnik, J M ^a   Spaide, R S ^a   Freund, K B ^a,b,c  

^a EAR AND THROAT HOSPITAL   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c New York Presbyterian Hospital   (United States)

Author keywords

Age related macular degeneration; Choroidal neovascularisation; Ranibizumab; Vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; MALE; PILOT STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETINA FOVEA; RETINA MACULA AGE RELATED DEGENERATION; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; SUBRETINAL FLUID; THICKNESS; TREATMENT DURATION; VISUAL ACUITY;

EID: 84867493598     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2012.174     Document Type: Article

References (13)

1. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-1444.
2. Freund KB, Zweifel SA, Engelbert M. Do we need a new classification for choroidal neovascularization in age-related macular degeneration? Retina 2010; 30: 1333-1349.
3. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-1431.
4. Group CR, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364: 1897-1908.
5. Engelbert M, Zweifel SA, Freund KB. Long-term follow-up for type 1 (subretinal pigment epithelium) neovascularization using a modified ''treat and extend'' dosing regimen of intravitreal antivascular endothelial growth factor therapy. Retina 2010; 30: 1368-1375.
6. Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 2005; 46: 726-733.
7. Rosenfeld P, Villate N, Feuer Wea. RhuFab V2 (anti-VEGF antibody fragment) in neovascular AMD: Safety, tolerability and efficacy of multiple, escalating dose intravitreal injections. Invest Ophthalmol Vis Sci 2003, ARVO 44, E-Abstract 970.
8. Ho AC. Efficacy and Safety of 2.0 mg and 0.5 mg Ranibizumab in Patients with Subfoveal Age-related Macular Degeneration: The HARBOR Study. American Academy of Ophthalmology: Orlando, USA, 2011.
9. Chen E, Mariani A, Brown DM. SAVE (Superdose AntiVEgf) Trial - 2.0-mg Intravitreal Ranibizumab for Recalcitrant Neovascular Age-Related Macular Degeneration (Poster). Association for Research in Vision and Ophthalmology: Fort Lauderdale, USA, 2011.
10. Chan C, Abraham P, Sarraf D, Nuthi ASD, Lin SG, McCannel CA. High-dose (2.0 mg) vs. 0.5mg Ranibizumab for Treating Vascularized Pigment Epithelial Detachment in Age-Related Macular Degeneration. American Academy of Ophthalmology: Orlando, USA, 2011.
11. Schaal S, Kaplan HJ, Tezel TH. Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration? Ophthalmology 2008; 115: 2199-2205.
12. Eghøj MS, Sørensen TL. Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol 2012; 96: 21-23.
13. Gasperini JL, Fawzi AA, Khondkaryan A, Lam L, Chong LP, Eliott D et al. Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation. Br J Ophthalmol 2012; 96: 14-20.